- Supported exchanges /
- F /
- 5HU.F
HEMOGENYX PHARM.PLC LS-01 (5HU F) stock market data APIs
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
HEMOGENYX PHARM.PLC LS-01 Financial Data Overview
| 0.0105 | |
| 0.0095 | |
| - | |
| 0.0105 | |
| 0.0095 | |
| 0.0005-0.052 | |
| 21 740 K | |
| 1 342 M | |
| 0 | |
| 3.145 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
HEMOGENYX PHARM.PLC LS-01 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -3 801 035
- Earnings Per Share -0.01
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get HEMOGENYX PHARM.PLC LS-01 Earnings via APIs
- Latest Release 2024-09-27
- EPS/Forecast NaN
Get HEMOGENYX PHARM.PLC LS-01 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
